Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
Enter any scientific lab and among the first tools
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micr
New Delhi: Caplin Point Laboratories on Thursday said its subsidiary has received approval from the US health regulator for Neostigmine Methylsulfate Injection. Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolariSing neuromuscular blocking agents (NMBAs) after surgery.
“Caplin Steriles Ltd (Caplin) has been granted final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Neostigmine Methylsulfate Injection USP in the strengths of 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL),” Caplin Point Laboratories said in a regulatory filing
Quoting IQVIA (IMS Health) data, Caplin Point Laboratories said Neostigmine Methylsulfate Injection had US sales data of approximately USD 20 million for the 12-month period ending Dec 2020.
